Kyverna Therapeutics (KYTX) Shares Outstanding (Diluted Average) (2023 - 2026)
Kyverna Therapeutics posted quarterly Shares Outstanding (Diluted Average) of $60.4 million for Q1 2026, up 39.84% year-on-year from $43.2 million in Q1 2025, and up 36.54% on a QoQ basis from $44.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Shares Outstanding (Diluted Average) data on file, last reported at $60.4 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 39.84% year-over-year to $60.4 million; the trailing twelve-month figure through Mar 2026 stood at $60.4 million (up 39.84% YoY), and the FY2025 full-year result was $44.3 million, up 15.46% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $60.4 million, up from $44.3 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $60.4 million in Q1 2026 and bottomed at $627589.0 in Q2 2023.
- The 4-year median for Shares Outstanding (Diluted Average) is $38.3 million (2024), against an average of $28.9 million.
- The widest annual swing landed in 2024, when Shares Outstanding (Diluted Average) surged 6721.72%; it then grew 0.6% in 2025.
- A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $673622.0 in 2023, then surged by 5590.81% to $38.3 million in 2024, then increased by 15.46% to $44.3 million in 2025, then jumped by 36.54% to $60.4 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $60.4 million (Q1 2026), $44.3 million (Q4 2025), and $43.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | 60.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.43 Mn |
| Dec 31, 2025 | 44.26 Mn |
| Sep 30, 2025 | 43.42 Mn |
| Jun 30, 2025 | 43.22 Mn |
| Mar 31, 2025 | 43.22 Mn |
| Dec 31, 2024 | 38.33 Mn |
| Sep 30, 2024 | 43.16 Mn |
| Jun 30, 2024 | 33.44 Mn |
| Mar 31, 2024 | 23.75 Mn |
| Dec 31, 2023 | 673,622.00 |
| Sep 30, 2023 | 632,624.00 |
| Jun 30, 2023 | 627,589.00 |
| Mar 31, 2023 | 921,260.00 |